Bristol-Myers Squibb (BMY), Otsuka America Launch Sprycel Patient Management Programs

Article Stock Quotes (1) Comments (0)

Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka America Pharmaceutical, Inc. today announced the launch of patient management programs for Sprycel (dasatinib) patients with a select group of specialty pharmacy providers. The specialty pharmacies include Accredo, CuraScript, Diplomat, Biologics and Avella (formerly The Apothecary Shops). The distribution of Sprycel will remain open to other specialty and retail pharmacies.

These patient management programs are consistent with Bristol-Myers Squibb’s customer-centric strategy and will mark an important initiative within Bristol-Myers Squibb.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: Leerink Swann Upgrades Bristol-Myers Squibb Co. (BMY) to Outperform
• Goldman Sees Blockbuster Potential for Bristol-Myers Squibb's (BMY) Nivolumab (PD-1)
• Santarus (SNTS) to Present Additional Data on UCERIS

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?